Heron Therapeutics (NASDAQ:HRTX) Hits New 12-Month Low at $16.19

Heron Therapeutics Inc (NASDAQ:HRTX) reached a new 52-week low on Friday . The stock traded as low as $16.19 and last traded at $16.31, with a volume of 536876 shares traded. The stock had previously closed at $17.13.

Several equities analysts recently weighed in on HRTX shares. BidaskClub upgraded Heron Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 18th. Cowen reiterated a “buy” rating on shares of Heron Therapeutics in a research report on Thursday, May 9th. Zacks Investment Research downgraded Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 9th. Northland Securities restated a “buy” rating and issued a $55.00 price objective on shares of Heron Therapeutics in a report on Thursday, May 9th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $38.00 price objective on shares of Heron Therapeutics in a report on Wednesday, May 1st. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $48.20.

The firm has a fifty day moving average price of $18.23. The stock has a market cap of $1.35 billion, a P/E ratio of -6.70 and a beta of 1.59. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.40 and a quick ratio of 4.06.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.30). The firm had revenue of $31.60 million during the quarter, compared to analysts’ expectations of $28.04 million. Heron Therapeutics had a negative return on equity of 49.22% and a negative net margin of 194.43%. The business’s revenue for the quarter was up 172.4% compared to the same quarter last year. During the same quarter last year, the business earned ($1.09) earnings per share. Equities research analysts anticipate that Heron Therapeutics Inc will post -2.66 earnings per share for the current year.

In related news, Director John Poyhonen bought 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were acquired at an average cost of $17.55 per share, for a total transaction of $52,650.00. Following the acquisition, the director now owns 13,000 shares in the company, valued at approximately $228,150. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Waage Christian bought 1,400 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The shares were bought at an average price of $18.04 per share, for a total transaction of $25,256.00. Following the completion of the acquisition, the director now owns 1,400 shares in the company, valued at approximately $25,256. The disclosure for this purchase can be found here. Company insiders own 12.56% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Lindbrook Capital LLC purchased a new stake in shares of Heron Therapeutics during the 2nd quarter valued at about $37,000. Parallel Advisors LLC raised its holdings in shares of Heron Therapeutics by 247.4% during the 1st quarter. Parallel Advisors LLC now owns 1,685 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 1,200 shares during the period. Pearl River Capital LLC raised its holdings in shares of Heron Therapeutics by 1,900.0% during the 1st quarter. Pearl River Capital LLC now owns 2,000 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,900 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Heron Therapeutics during the 1st quarter valued at about $151,000. Finally, Laurion Capital Management LP purchased a new stake in shares of Heron Therapeutics during the 1st quarter valued at about $216,000.

About Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Article: What does relative strength index mean?

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.